

# Accelerating Population Proteomics



## Standard BioTools is Committed to:



**Proteomics Excellence:** Delivering the most comprehensive, reliable and trusted proteomic platforms for the global biobank community, supporting discovery of new targets and biomarkers to improve human health.



**Clinical Translation:** Supporting the translation of biobank discoveries to advance new drug candidates, accelerate clinical trials, and matching patients with healthcare services and treatments for optimal benefits.



**Business Partnership:** Providing innovative, high quality life science tools to the research community while creating long term collaborative relationships.

## The SomaScan® Platform provides powerful and durable data standards for population proteomics

### 1. Unmatched Coverage of the Human Proteome

11,000 protein measurements in a 55  $\mu$ L sample means the greatest yield of genetic associations and biomarkers for research in disease biology and drug targets.

### 2. Proven Scalability

As our Assay content and throughput have expanded, precision, sensitivity, and specificity have been maintained – across time while demonstrating consistency between different centers for data comparison.

### 3. Exquisite Specificity

Slow Off-rate Modified Aptamer (SOMAmer®) Reagents are identified via our unique selection, SELEX process, against epitopes on a single target protein and characterized and validated through extensive specificity testing.

### 4. Precision & Reproducibility

Chemically synthesized SOMAmer Reagents ensure consistency over time. Inter-assay CVs of 5% enable detection of subtle biological signals with fewer samples. Standardized calibrators and controls run with every plate underpin direct analysis across cohorts for discovery at population scale.

### 5. Cost-effective

Standard BioTools is committed to partnering with global biobank stakeholders for cost-effective studies at population scale.

### 6. Standard business terms

Straightforward fee-for-service / fee-for-product terms.

## Standard BioTools offers value-added features unmatched by other proteomic platforms



### Data and health insights

Validated proteomics models for clinical phenotypes available to characterize individual health status, stratify clinical trial populations and improve medical decision making worldwide.



### SomaScan Assay adoption/kits

Standard BioTools's unique sample assessment tool ensures high quality and consistent protein identification, whether you choose to run samples at our CLIA-certified service lab or at a worldwide certified Authorized Site.



### SOMAmer affinity binding reagents

The protein/epitope specific SOMAmer Reagents used in our SomaScan Assay are available as individual reagents for follow up for mass spec pulldowns, cellular assays, biomarker assays and target validation.



### Pre-analytical sample quality assessments

Avoid experimental failure and extra costs by knowing which samples have degraded, the cause and extent, and how to manage sample variability. PAV tests are currently available for SomaScan 7K Assay.

## The SomaScan Platform advances proteomic innovation

1. Protein coverage on a path to grow beyond 11,000 protein measurements. Each new version of the SomaScan Assay provides enhanced data quality and performance with expanded protein coverage while maintaining reproducibility across versions.
2. Partnership with Illumina to develop a next-generation sequencing readout for the SomaScan Assay.
3. Validated workflows with industry-leading partners using SOMAmer Reagents for mass spec and specialized applications, such as single-cell spatial proteomics, small-plex quantitative assays.
4. Combined use of SOMAmer Reagents enable measurement of multiple protein epitopes simultaneously to elucidate biologically relevant proteoforms (e.g., PTM, cis-pQTL).
5. Expanding menu of protein biomarker (RUO) and validated clinical tests (LDTs) to stratify clinical trials and target clinical interventions, and improve population health.
6. Business and technology platform available to support development of new protein-based clinical tests by biobank stakeholders.

## Standard BioTools is the leader in population proteomics, supporting a large number of biobank studies worldwide



SL00000823 Rev 3 2024-06

### Industry-Leading Population Proteomics

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: [www.standardbio.com/legal/salesterms](http://www.standardbio.com/legal/salesterms). Patent and License Information: [www.standardbio.com/legal/notices](http://www.standardbio.com/legal/notices).

Trademarks: [www.standardbio.com/legal/trademarks](http://www.standardbio.com/legal/trademarks).

SomaLogic, SomaScan, SOMAmer, SomaSignal, DataDelve, LabThreadSLX and associated logos are trademarks of SomaLogic Operating Co., Inc., a wholly owned subsidiary of Standard BioTools Inc. Patent and Trademarks: <https://somalogic.com/list-of-patents/>. Any other trademarks are the sole property of their respective owners.

©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.